Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimetridazole SCHEMBL10455000 | 0.98 | LMNA (0.57) | LMNAALDH1A1MAPK1THRBTSHR | |
| Dimetridazole SCHEMBL29886852 | 0.86 | LMNA (0.50) | LMNAALDH1A1MAPK1THRBTSHR | |
| Secnidazole SCHEMBL28208800 | 0.81 | MAPK1 (0.86) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL11619443 | 0.78 | LMNA (0.46) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL20375687 | 0.78 | LMNA (0.50) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL19402556 | 0.78 | LMNA (0.53) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL11831842 | 0.78 | LMNA (0.46) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL9490979 | 0.78 | ALDH1A1 (0.53) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL27704271 | 0.78 | ALDH1A1 (0.53) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL3281642 | 0.78 | LMNA (0.49) | LMNAALDH1A1MAPK1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1750 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078296-A1 | SUSTAINED-RELEASE SCALE INHIBITORS | Materials Engineering and Technical Support Services (US) | 2026-03-19 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-12496548-B2 | Hydrophobic MOF-based porous liquid carbon capture absorbent and preparation method therefor | HUANENG CLEAN ENERGY RESEARCH INSTITUTE (CN) | 2025-12-16 | — | — | US | claimed |
| US-20250268934-A1 | Compositions and Methods for the Treatment of Bacterial Vaginosis | WAYNE STATE UNIVERSITY (US) | 2025-08-28 | — | — | US | claimed |
| WO-2025085790-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VAGINITIS | WAYNE STATE UNIVERSITY (US) | 2025-04-24 | — | — | WO | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| EP-4507693-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL VAGINOSIS | Wayne State University (US) | 2025-02-19 | — | — | EP | claimed |
| US-20250032455-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2025-01-30 | — | — | US | claimed |
| US-12171748-B2 | Nitroimidazole formulations | IRP Health Pty Ltd (AU) | 2024-12-24 | — | — | US | claimed |
| US-20240382899-A1 | Hydrophobic MOF-Based Porous Liquid Carbon Capture Absorbent and Preparation Method Therefor | SHANGHAI SHIDONGKOU NO. 2 POWER PLANT HUANENG INTERNATIONAL POWER CO. LTD (CN) | 2024-11-21 | — | — | US | claimed |
| US-4920141-A | MIXTURE OF WATER SOLUBLE SALT OF METRONIDAZOLE, DIMETRIDAZOLE, SECNIDAZOLE OR IPRONIDAZOLE AND GLUTARALDEHYDE; INDUSTRIAL WATER TREATMENT | PETROLITE CORPORATION (US) | 1990-04-24 | — | — | US | claimed |
| US-4701331-A | Non-dusty blends of meals or flours with active principles for use in fodder production | DOX-AL ITALIA SPA (IT) | 1987-10-20 | — | — | US | claimed |
| US-4662905-A | REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE | Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) | 1987-05-05 | — | — | US | claimed |
| EP-0072919-B1 | PROCESS FOR THE PREPARATION OF 1,2-DIMETHYL-5-NITROIMIDAZOLE OF HIGH PURITY | BASF Aktiengesellschaft (DE) | 1986-01-08 | — | — | EP | claimed |
| EP-0146738-A2 | Antimicrobial animal feed additive compositions | AMERICAN CYANAMID COMPANY (US) | 1985-07-03 | — | — | EP | claimed |
| EP-0043922-B1 | PROCESS FOR PREPARING 1,2-DIMETHYL-5-NITROIMIDAZOLE | BASF Aktiengesellschaft (DE) | 1984-09-19 | — | — | EP | claimed |
| EP-0072919-A1 | Process for the preparation of 1,2-dimethyl-5-nitroimidazole of high purity | BASF Aktiengesellschaft (DE) | 1983-03-02 | — | — | EP | claimed |
| US-4339448-A | Imidazole-copper complex compounds and fungicides containing them | BASF AKTIENGESELLSCHAFT (DE) | 1982-07-13 | — | — | US | claimed |
| EP-0043922-A1 | Process for preparing 1,2-dimethyl-5-nitroimidazole | BASF Aktiengesellschaft (DE) | 1982-01-20 | — | — | EP | claimed |
| US-3952007-A | Processes for preparing 5-nitro-1-methyl-2-(2-dialkylaminovinyl)-imidazole and 5-nitro-1-methyl-2-imidazolyl carboxaldehyde | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078296-A1 | SUSTAINED-RELEASE SCALE INHIBITORS | CEL, TST, CD44 | LMNA 3849/4885ALDH1A1 1392/4885MAPK1 4020/4885 |
| US-12171748-B2 | Nitroimidazole formulations | PHB1, COX5B, CYP3A5 | LMNA 3271/4885ALDH1A1 3471/4885MAPK1 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.